PE20141109A1 - Anticuerpos anti-notch 1 - Google Patents

Anticuerpos anti-notch 1

Info

Publication number
PE20141109A1
PE20141109A1 PE2013001423A PE2013001423A PE20141109A1 PE 20141109 A1 PE20141109 A1 PE 20141109A1 PE 2013001423 A PE2013001423 A PE 2013001423A PE 2013001423 A PE2013001423 A PE 2013001423A PE 20141109 A1 PE20141109 A1 PE 20141109A1
Authority
PE
Peru
Prior art keywords
antibody
seq
referred
variable region
notch antibodies
Prior art date
Application number
PE2013001423A
Other languages
English (en)
Spanish (es)
Inventor
G Kenneth Geles
Bin-Bing Stephen Zhou
Lioudmila Gennadievna Tchistiaova
Yijie Gao
Joel Bard
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PE20141109A1 publication Critical patent/PE20141109A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
PE2013001423A 2010-12-15 2011-12-09 Anticuerpos anti-notch 1 PE20141109A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42357810P 2010-12-15 2010-12-15
US201161552578P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
PE20141109A1 true PE20141109A1 (es) 2014-09-24

Family

ID=45444674

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001423A PE20141109A1 (es) 2010-12-15 2011-12-09 Anticuerpos anti-notch 1

Country Status (19)

Country Link
US (2) US9127060B2 (cg-RX-API-DMAC7.html)
EP (1) EP2651977A2 (cg-RX-API-DMAC7.html)
JP (1) JP6016800B2 (cg-RX-API-DMAC7.html)
KR (2) KR20150088334A (cg-RX-API-DMAC7.html)
CN (2) CN103547594B (cg-RX-API-DMAC7.html)
AR (1) AR084315A1 (cg-RX-API-DMAC7.html)
AU (2) AU2011342799B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013015122A2 (cg-RX-API-DMAC7.html)
CA (1) CA2821130C (cg-RX-API-DMAC7.html)
CO (1) CO6791565A2 (cg-RX-API-DMAC7.html)
MX (1) MX346995B (cg-RX-API-DMAC7.html)
NZ (1) NZ611785A (cg-RX-API-DMAC7.html)
PE (1) PE20141109A1 (cg-RX-API-DMAC7.html)
PH (2) PH12013501255A1 (cg-RX-API-DMAC7.html)
RU (1) RU2622083C2 (cg-RX-API-DMAC7.html)
SA (1) SA111330060B1 (cg-RX-API-DMAC7.html)
SG (1) SG191039A1 (cg-RX-API-DMAC7.html)
TW (1) TWI471333B (cg-RX-API-DMAC7.html)
WO (1) WO2012080926A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032166B1 (en) 2006-06-13 2013-04-10 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
EP2443151A1 (en) 2009-06-18 2012-04-25 Pfizer Inc. Anti notch-1 antibodies
JP6016800B2 (ja) 2010-12-15 2016-10-26 ワイス・エルエルシー 抗ノッチ１抗体
US20150209406A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2014047426A1 (en) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
TW201431880A (zh) 2012-11-07 2014-08-16 Pfizer 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2017072208A1 (en) * 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Transgenic rabbit with common light chain
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
JP7562417B2 (ja) * 2018-04-10 2024-10-07 スティヒティング・サンクイン・ブルートフォールズィーニング キメラノッチ受容体
CN113365697B (zh) * 2018-09-25 2024-07-19 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
KR102499678B1 (ko) * 2020-02-27 2023-02-15 주식회사 베르티스 암의 진단용 조성물
US20240067711A1 (en) * 2020-08-31 2024-02-29 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN1331214A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人缺刻蛋白24.64和编码这种多肽的多核苷酸
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
CN1376686A (zh) * 2001-03-22 2002-10-30 上海博德基因开发有限公司 一种多肽——缺刻蛋白－34.32和编码这种多肽的多核苷酸
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20030148954A1 (en) 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
EP1448599A2 (en) 2001-11-14 2004-08-25 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
WO2004009617A1 (ja) 2002-07-18 2004-01-29 Osaka Industrial Promotion Organization Ｎｏｔｃｈ由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
AU2004294563B2 (en) 2003-11-26 2009-03-26 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
WO2006001956A2 (en) 2004-05-20 2006-01-05 The Board Of Trustees Of The University Of Illinois Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
AU2005302846A1 (en) * 2004-11-10 2006-05-18 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CA2600908A1 (en) 2005-03-04 2006-09-08 The Hospital For Sick Children Methods for cancer prognosis
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
WO2007061988A2 (en) 2005-11-22 2007-05-31 University Of Vermont And State Agricultural College Methods for determining notch signaling and uses thereof
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
EP2032166B1 (en) 2006-06-13 2013-04-10 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN101605815B (zh) * 2006-12-18 2013-11-13 健泰科生物技术公司 拮抗性抗刻缺蛋白3抗体及其在预防和治疗刻缺蛋白3相关疾病中的用途
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
PT2307051E (pt) 2008-07-08 2015-05-21 Oncomed Pharm Inc Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
EP2443151A1 (en) 2009-06-18 2012-04-25 Pfizer Inc. Anti notch-1 antibodies
MA33973B1 (fr) 2009-09-30 2013-02-01 Genentech Inc Méthodes de traitement du cancer à l'aide d'antagonistes de notch
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
JP6016800B2 (ja) 2010-12-15 2016-10-26 ワイス・エルエルシー 抗ノッチ１抗体

Also Published As

Publication number Publication date
CN103547594B (zh) 2016-05-11
AU2011342799B2 (en) 2016-06-09
PH12017500864A1 (en) 2017-12-11
AR084315A1 (es) 2013-05-08
KR20150088334A (ko) 2015-07-31
JP6016800B2 (ja) 2016-10-26
TWI471333B (zh) 2015-02-01
WO2012080926A3 (en) 2012-10-04
CO6791565A2 (es) 2013-11-14
CN103547594A (zh) 2014-01-29
AU2016219704A1 (en) 2016-09-15
NZ611785A (en) 2015-04-24
MX2013006875A (es) 2013-07-05
MX346995B (es) 2017-04-06
JP2014503205A (ja) 2014-02-13
CA2821130A1 (en) 2012-06-21
SG191039A1 (en) 2013-08-30
RU2622083C2 (ru) 2017-06-09
EP2651977A2 (en) 2013-10-23
US9127060B2 (en) 2015-09-08
PH12013501255A1 (en) 2013-08-05
US20160002331A1 (en) 2016-01-07
KR101580726B1 (ko) 2015-12-29
AU2011342799A1 (en) 2013-07-04
HK1194388A1 (zh) 2014-10-17
TW201302787A (zh) 2013-01-16
US20130266594A1 (en) 2013-10-10
CA2821130C (en) 2017-11-07
WO2012080926A2 (en) 2012-06-21
RU2013126494A (ru) 2015-01-20
KR20130108430A (ko) 2013-10-02
SA111330060B1 (ar) 2015-06-04
CN105884896A (zh) 2016-08-24
BR112013015122A2 (pt) 2017-05-30

Similar Documents

Publication Publication Date Title
PE20141109A1 (es) Anticuerpos anti-notch 1
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20150002A1 (es) Anticuerpos anti-fcrn
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
PE20200148A1 (es) Anticuerpos anti-trem2 y metodos para utilizarlos
ECSP19022190A (es) Construcciones de inmunoglobulina heterodiméricas y métodos de preparación de las mismas
PE20091172A1 (es) Anticuerpos bivalentes biespecificos
PE20140247A1 (es) Anticuerpos anti-cd38
EA201791422A1 (ru) Фармацевтические продукты и устойчивые жидкие композиции антител к il-17
EA201400875A1 (ru) Антитела к cd47 и способы их применения
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
PE20081478A1 (es) Anticuerpos cd44
PE20180481A1 (es) Anticuerpos de union a tau
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201992206A1 (ru) Моноклональное антитело к pd-l1

Legal Events

Date Code Title Description
FC Refusal